July 16, 2024

Zepbound, a newly accredited weight-loss drug, is now out there in U.S. pharmacies, drugmaker Eli Lilly introduced on Tuesday.

“The supply of Zepbound in U.S. pharmacies is step one, however we have now to work hand-in-hand with employers, authorities and healthcare trade companions to take away obstacles and make Zepbound out there to those that want it,” mentioned Rhonda Pacheco, an govt with Eli Lilly. 

Zepbound is a once-weekly injectable remedy. Customers will begin at a 2.5-milligram dosage and regularly enhance to fifteen milligrams.  

The remedy is a part of a category of medicine known as GLP-1 agonists, which activate hormone receptors to cut back urge for food and meals consumption. It is much like semaglutide injections generally known as Ozempic and Wegovy, that are additionally prescribed for weight reduction.

In medical trials, the Meals and Drug Administration mentioned Zepbound was discovered to cut back physique weight by 18% over 72 weeks of remedy in adults with out diabetes when mixed with a reduced-calorie weight loss plan and train. For adults with diabetes, physique weight was lowered by 12%.

There’s a value barrier for individuals who need to get on Zepbound. It prices $1,059 monthly with out insurance coverage. Nonetheless, Eli Lilly mentioned its financial savings card program is offered at U.S. pharmacies. It should permit folks with qualifying insurance coverage to pay as little as $25 for as much as a three-month provide. 


Supply Hyperlink : [randomize]